Background: Sex steroids are prominent regulators of pulsatile GH secretion. Hypothesis: An experimentally controlled sex-steroid milieu will permit detection of nonsteroidal factors that determine GH secretion. Subjects: Eleven young (age, 24 ± 0.99 yr) and 11 older (64 ± 2.4 yr) men participated in the study. Location: The study was conducted at a tertiary medical center. Methods: The study consisted of GnRH-agonist down-regulation of the gonadal axis followed by fixed-dose testosterone (T) replacement (leuprolide/T clamp) and consecutive infusion of L-arginine and GHRH or GH-releasing peptide-2 (GHRP-2) to quantify peptide-secretagogue efficacies. Outcomes: The experimental leuprolide/T clamp yielded statistically age-comparable total, bioavailable, and free T and estradiol (E2) concentrations. In this controlled milieu, sequential L-arginine/GHRH infusion stimulated 1.4-fold more (P = 0.021) and L-arginine/GHRP-2 1.3-fold more (P = 0.045) GH release in young than older men. Abdominal visceral fat (AVF) correlated negatively with both GHRH (P = 0.0006; R2 = 0.39) and GHRP-2 (R2 = 0.29) efficacy, whereas IGF-I positively predicted the same endpoints (R2 = 0.25 to 0.30). In multivariate analysis, AVF emerged as a dominant negative determinant of GHRH efficacy (P = 0.002; R 2 = 0.41) and IGF-I as a primary positive determinant of GHRP-2 efficacy (P = 0.007; R2 = 0.31). Conclusion: During fixed T/E 2 availability, AVF contributes 41% of the GH-response variability to maximal GHRH drive, whereas IGF-I accounts for 31% of that for GHRP-2. Accordingly, a statistically equalized sex-steroid milieu permits dissection of age-independent and T/E2-independent modulators of GHRH and GHRP efficacy in men.
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Clinical Biochemistry
- Biochemistry, medical